# AstraZeneca’s Imfinzi four-week dosing approved in the US

- Link: https://www.directorstalkinterviews.com/astrazenecas-imfinzi-four-week-dosing-approved-in-the-us/412938871
- Published: 2020-11-20T07:31:10+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Imfinzi_ has been approved in the US for an additional dosing option, a 1,500mg
fixed dose every four weeks, in the approved indications of unresectable Stage III
non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously
treated advanced bladder cancer. This new option is consistent with the approved
_Imfinzi_ dosing in extensive-stage small cell lung cancer (ES-SCLC) and will be
available to patients weighing more than 30kg as an alternative to the approved 
weight-based dosing of 10mg/kg every two weeks.

The approval by the Food and Drug Administration (FDA) was based on data from several
_Imfinzi_ clinical trials, including the PACIFIC Phase III trial which supported
the two-week, weight-based dosing in unresectable Stage III NSCLC, and the CASPIAN
Phase III trial which used four-week, fixed-dosing during maintenance treatment 
in ES-SCLC. The decision follows the Priority Review granted by the FDA in August
2020.

> **Victoria M. Villaflor, MD, Clinical Professor in the Department of Medical Oncology
> and Therapeutics Research at City of Hope Cancer Center, Los Angeles, California,
> said:** “This new four-week dosing option gives doctors the choice to cut the 
> number of visits for critical cancer treatment in half and offers a regimen that
> is more convenient for patients. Additionally, it limits potential exposure to
> infection in the healthcare environment for a population that is especially vulnerable
> to complications from COVID-19.”

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said:** “
> The approval of this new dosing option across indications reflects our ongoing
> commitment to improve the patient experience and ensure continuity of care – a
> priority at all times, but especially during the pandemic. Cancer won’t wait, 
> and it is our job to provide patients with treatment options that acknowledge 
> the challenges the pandemic poses to cancer care, enabling them to visit their
> physician when truly needed and avoid preventable exposure to healthcare-associated
> infections.”

The four-week 1,500mg fixed-dosing option for _Imfinzi_ is also under regulatory
review in several other countries, including in the EU where the new dosing option
was granted accelerated assessment.

_Imfinzi_ is approved in the curative-intent setting of unresectable, Stage III 
NSCLC after CRT in the US, in the EU, in Japan, in China and in many other countries,
based on the PACIFIC Phase III trial. _Imfinzi_ is also approved for previously 
treated patients with advanced bladder cancer in the US and several other countries.
Additionally, it is approved in the US, the EU, Japan and several other countries
around the world for the treatment of ES-SCLC based on the CASPIAN Phase III trial.

**Stage III NSCLC**

Stage III NSCLC (locally advanced) is commonly divided into three sub-categories(
IIIA, IIIB and IIIC), defined by how much the cancer has spread locally and the 
possibility of surgery.^(1) Stage III disease is different from Stage IV disease,
where the cancer has spread (metastasised), as the majority of Stage III patients
are currently treated with curative intent.^(1,2)

Stage III NSCLC represents approximately one third of NSCLC incidence and in 2015
was estimated to affect nearly 200,000 patients in the following eight large countries:
China, France, Germany, Italy, Japan, Spain, UK, and the US, with approximately 
43,000 cases in the US alone.^(3,4) The majority of Stage III NSCLC patients are
diagnosed with unresectable tumours.^(5) Prior to approval of _Imfinzi_ in this 
setting, no new treatments beyond CRT had been available to patients for decades.
^(6-8)

**Small cell lung cancer**

SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs
and progresses rapidly, despite initial response to chemotherapy.^(9,10) About two
thirds of SCLC patients are diagnosed with extensive-stage disease, in which the
cancer has spread widely through the lung or to other parts of the body.^(11) Prognosis
is particularly poor, as only 6% of all SCLC patients will be alive five years after
diagnosis.^(11)

**Bladder cancer**

In 2018, approximately 550,000 people were diagnosed with bladder cancer around 
the world and 200,000 died from the disease.^(12) Locally advanced and metastatic
bladder cancer remains an area of unmet medical need and typically only one in seven
patients is alive five years after diagnosis.^(13) Urothelial cancer (UC) is the
most common form of bladder cancer.^(14) UC is the 10th most common cancer worldwide
and the 13th most common cause of cancer death.^(12,15) PD-L1 is widely expressed
in tumour and immune cells in patients with bladder cancer and helps tumours evade
detection from the immune system.^(16)

**Imfinzi**

_Imfinzi_ (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks
the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading
tactics and releasing the inhibition of immune responses.

As part of a broad development programme, _Imfinzi_ is also being tested as a monotherapy
and in combinations including with tremelimumab, an anti-CTLA4 monoclonal antibody
and potential new medicine, as a treatment for patients with NSCLC, SCLC, bladder
cancer, head and neck cancer, liver cancer, biliary tract cancer, oesophageal cancer,
gastric cancer, cervical cancer, ovarian cancer, endometrial cancer and other solid
tumours.

**AstraZeneca in lung cancer**

AstraZeneca has a comprehensive portfolio of approved and potential new medicines
in late-stage development for the treatment of different forms of lung cancer spanning
different histologies, several stages of disease, lines of therapy and modes of 
action.

An extensive Immuno-Oncology (IO) development programme focuses on lung cancer patients
without a targetable genetic mutation, which represent up to three-quarters of all
patients with lung cancer.^(17) _Imfinzi_, an anti-PDL1 antibody, is in development
for patients with advanced disease (POSEIDON and PEARL Phase III trials) and for
patients in earlier stages of disease, including potentially-curative settings (
MERMAID-1, AEGEAN, ADJUVANT BR.31, PACIFIC-2, PACIFIC-4, PACIFIC-5, and ADRIATIC
Phase III trials) both as monotherapy and in combination with tremelimumab and/or
chemotherapy. 

_Imfinzi_ is also in development in the Phase II trials NeoCOAST, COAST and HUDSON
in combination with potential new medicines from the early-stage pipeline, including
_Enhertu_ (trastuzumab deruxtecan).

Share on:
